Opinion|Videos|June 4, 2025
Novel Treatment Options for Bronchiectasis
Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.
Advertisement
Episodes in this series
Clinical Brief: Emerging Therapies for Bronchiectasis
Main Discussion Topics
- DPP1 inhibitors target neutrophil inflammation in bronchiectasis.
- Eosinophilic bronchiectasis (approximately 30% of cases) benefits from targeted therapies.
- Approaches to treatment vary based on inflammatory phenotype.
Key Points for Physicians
- DPP1 inhibitors:
- Target abnormal neutrophil function and reduce neutrophil serine proteases
- May prevent formation of neutrophil extracellular traps
- Aim to reduce exacerbations and disease progression
- For eosinophilic bronchiectasis (30% of cases):
- Inhaled corticosteroids are beneficial
- Anti-IL5 therapies show promise
- Biologic therapies are being investigated
- Discourage inhaled corticosteroids in neutrophilic bronchiectasis (70% of cases) due to potential infection risk.
Notable Insights
Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.
Clinical Significance
Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.
Advertisement
Related to this article
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, and quality of life.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
Advertisement
Advertisement
Trending on AJMC
1
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
2
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
3
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5